Prozac Starting Dose for Adults
The recommended starting dose of fluoxetine (Prozac) for adults is 20 mg once daily, administered in the morning 1.
Dosing Recommendations by Indication
Major Depressive Disorder
- Standard starting dose: 20 mg/day in the morning 1
- This dose is sufficient to obtain a satisfactory response in most cases, as demonstrated in controlled trials comparing 20,40, and 60 mg/day to placebo 1
- Dose increases may be considered after several weeks if insufficient clinical improvement is observed
- Maximum dose: 80 mg/day
Important caveat: While 20 mg is the FDA-approved starting dose, some patients—particularly those with panic disorder or high anxiety sensitivity—may benefit from initiating at a lower dose of 5-10 mg/day and titrating up over 1 week 2. A study of 133 depressed outpatients found that 28% could not tolerate the full 20 mg dose, with half of these patients doing well clinically on lower doses 2. This lower-dose initiation strategy may be particularly beneficial for patients with comorbid panic disorder.
Obsessive-Compulsive Disorder
- Starting dose: 20 mg/day in the morning 1
- May require higher doses (40-60 mg/day) for optimal response
- Full therapeutic effect may be delayed until 5 weeks or longer
Panic Disorder
- Starting dose: 10 mg/day for 1 week, then increase to 20 mg/day 1
- This gradual titration helps minimize initial anxiety or agitation that can occur with SSRIs 3
Bulimia Nervosa
- Target dose: 60 mg/day (not a starting dose) 1
- May titrate up to this target over several days
- Only the 60 mg dose was statistically superior to placebo in controlled trials
Special Populations
Elderly Patients
- Consider lower or less frequent dosing 1
- The guidelines from 2002 for Alzheimer's patients suggest starting at 10 mg every other morning 4
Hepatic Impairment
- Use lower or less frequent dosage 1
Pediatric Patients (Children and Adolescents)
- Starting dose: 10 mg/day 5, 1
- After 1 week at 10 mg/day, increase to 20 mg/day
- For lower weight children, 10 mg/day may be both the starting and target dose
Key Clinical Considerations
Onset of action: The full therapeutic effect may be delayed until 4 weeks of treatment or longer 1. This is due to the multistep neurobiological process involving downregulation of serotonin autoreceptors 6.
Activating properties: Fluoxetine is described as "activating" with a very long half-life 4. Because an initial adverse effect can be anxiety or agitation, starting with a subtherapeutic "test" dose may be advisable in anxious patients 6.
Pharmacokinetics: Fluoxetine has a long elimination half-life (1-3 days after single dose, averaging 4 days after long-term administration), and its active metabolite norfluoxetine has an even longer half-life (averaging 7 days) 7. This protects against withdrawal symptoms but requires at least 5 weeks washout before starting an MAOI 1.
Monitoring: Close monitoring for suicidality is recommended, especially in the first months of treatment and following dosage adjustments, particularly in patients under age 24 6, 5.